The Global Venous Thromboembolism Treatment Industry is on an upward trajectory, with a projected compound annual growth rate (CAGR) of approximately 3.7% between 2022 and 2029, according to a recent study by Future Market Insights (FMI).
The market’s steady rise is underpinned by the strong demand for venous thromboembolism treatment, with deep venous thrombosis accounting for more than 3/5th of the treatment demand, as highlighted in the report. Catheter-directed thrombolysis devices and percutaneous thrombectomy devices collectively contribute to over half of the market’s global revenues.
The Venous Thromboembolism Treatment Industry encompasses a range of innovative solutions, including segmented pneumatic compression pumps with and without calibrated gradient, lower pneumatic compression sleeves, non-segmented pneumatic compression pumps, permanent and retrievable inferior vena cava filters, embolectomy balloon catheters, and catheter-directed thrombolysis (CDT) devices. Additionally, upper pneumatic compression sleeves are part of this dynamic landscape.
Deep vein thrombosis, based on disease indication, is expected to maintain a prominent share in the overall Venous Thromboembolism Treatment Industry. This growing demand for advanced treatments underscores the market’s potential for transformative growth.
Request a Sample Report Now to get Premium Insights:
https://www.futuremarketinsights.com/reports/sample/rep-gb-1341
Poor Reimbursement Scenario against High Treatment Costs to Restrict Adoption
Several factors are impacting the overall growth of the venous thromboembolism treatment Industry. The first and the most important factor driving the venous thromboembolism treatment market is the increasing prevalence of venous thromboembolism disease. Other factors, such as the increasing retrieval rate of vena cava filters, increasing healthcare awareness, presence of favourable reimbursement policies, and increasing geriatric population, are also responsible for the growth of the venous thromboembolism treatment Industry.
Apart from the driving factors of venous thromboembolism treatment Industry, there are few factors that are likely to hinder the overall growth of the venous thromboembolism treatment market. The high cost associated with venous thromboembolism treatment therapy, poor reimbursement for some of the treatment devices, and poor insurance support are among the major factors that are expected to hamper the growth of the venous thromboembolism treatment Industry.
Drug-based Treatment Witnessing Traction across Europe
Although increasing preference for drug-based venous thromboembolism treatment is highly likely to hinder the growth of the market, new-generation drugs, including non-Vitamin K antagonist oral anticoagulants (NOACs) such as dabigatran, rivaroxaban, apixaban, and edoxaban, are estimated to boost the adoption rate of venous thromboembolism treatment due to increased efficacy. However, there are regional variations to this trend.
Discovering the assumptions behind the study. Ask the Expert.
https://www.futuremarketinsights.com/ask-question/rep-gb-1341
North America is expected to be a prominent region in the global venous thromboembolism treatment market because of the presence of a well-developed healthcare infrastructure and numerous technological advancements in the region. The increasing prevalence of venous thromboembolism is also responsible for the boosting the growth of the North America market. Treatment using mechanical and interventional prophylaxis systems is expected to be increasingly adopted in the North American region during the forecast period. In addition, drug-based treatment is expected to gain popularity in the European region, which is expected to subsequently decrease the usage of mechanical and interventional treatments in the region.
On the other hand, increasing per capita healthcare expenditure is one of the macroeconomic factors that is likely to boost the market. Nowadays, certain changes in the socio-economic scenario can also lead to significant growth in the venous thromboembolism treatment Industry.
Tier 1 Players Account for Nearly 35% Market Revenue Share
Some of the key manufacturers of venous thromboembolism treatment are mainly focusing on innovating and launching new and advanced products. Major players in the venous thromboembolism treatment Industry are focusing on collaborations and acquisitions. For example, hospitals, catheterisation laboratories, and ambulatory surgical centres majorly adopt venous thromboembolism treatment. Hospitals are expected to hold a significant revenue share in the venous thromboembolism treatment market.
The report tracks some of the key companies operating in the venous thromboembolism treatment Industry such as ArjoHuntleigh AB, AngioDynamics, Cardinal Health Inc., BTG International Ltd., Stryker Corporation, DJO Global Inc., EKOS Corp, and Teleflex Inc., Boston Scientific Corp. There are several other companies operating in the venous thromboembolism treatment Industry. AngioDynamics, Boston Scientific Corp., and Cardinal Health Inc. are expected to hold a prominent share in the venous thromboembolism treatment market. These tier 1 companies hold a share of approximately 35% in the venous thromboembolism treatment Industryt.
Access Exclusive Market Insights – Purchase Now!
https://www.futuremarketinsights.com/checkout/1341
Global Venous Thromboembolism Treatment Industry by Category By Product:
- Non-Segmented Pneumatic Compression Pumps
- Segmented Pneumatic Compression Pumps without Gradient
- Segmented Pneumatic Compression Pumps with Calibrated Gradient
- Upper Pneumatic Compression Sleeves
- Lower Pneumatic Compression Sleeves
- Permanent Inferior Vena Cava Filters
- Retrievable Inferior Vena Cava Filters
- Embolectomy Balloon Catheters
- Percutaneous Thrombectomy Devices
- Catheter-Directed Thrombolysis (CDT) Devices
By Disease Indication:
- Deep Venous Thrombosis
- Pulmonary Embolism
By End User:
- Hospitals
- Catheterisation Laboratories
- Ambulatory Surgical Centers
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube